Neogap chosen for Innovate Nordics 2025 Acceleration Programme
Ella Day | May 1, 2025 | News story | Research and Development |Â Â Innovate Nordics, Neogap Therapeutics, Oncology, biotech, funding programme, immunotherapyÂ
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics’ 2025 acceleration programme, a prestigious initiative designed to help Nordic growth companies expand into the US market.
Organised by the Swedish-American Chamber of Commerce in New York (SACCNY) in partnership with EY, the programme provides selected companies with access to US investor networks, market entry support and business development resources. Past participants include Anyo Labs, BrainZell, Epigenica, Ironic Biotech, Mavatar, MedBeat and VIDEM.
Neogap was selected for its strong potential in the US healthcare market, particularly for its work on personalised cancer immunotherapy. The company’s leading treatment, pTTL – a personalised, cell-based therapy – enhances a patient’s T-cells to fight cancer using a combination of DNA sequencing and T-cell expansion. The therapy recently reported positive safety results from a phase 1 trial in patients with advanced colorectal cancer.
Neogap will be featured at the programme’s kick-off event in Stockholm, Sweden on 8 May and will later present at the Grand Pitch Finale in New York, US.
“We are honoured to have been selected for Innovate Nordics 2025,” said Andrea Salmén, COO at Neogap Therapeutics. “The programme offers us a valuable opportunity to strengthen existing relationships, build new ones, and increase our access to the US market. Each step brings us closer to our goal – making personalised cancer immunotherapy available to more patients.”
Ella Day
1/5/25
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
